Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Czechia
Clinical trial register · European Union · CTIS

Clinical Trials in Czechia, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2556 most recently authorised of 12893 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Nov 2026, 03:17 UTC
2556
Shown in this register
most recently authorised
12,893
Total on CTIS
full historical archive
785
Phase III
within the shown window
Top member states
Spain 1069 France 921 Germany 906 Italy 769 Poland 620 Netherlands 547

Trials with a site in Czechia

344 of 2556 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
Rapport Therapeutics Inc.
Nervous System Diseases
Denmark, Czechia, Lithuania, Portugal, Greece, Germany, Spain, Finland, Netherlands
18/11/2026
Phase II
AbbVie Deutschland GmbH & Co. KG
Digestive System Diseases
Netherlands, Belgium, Greece, Spain, Lithuania, Germany, Czechia, Italy, Portugal, Sweden
17/11/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Spain, Belgium, France, Germany, Czechia, Greece
16/11/2026
Phase III
Pulmovant Inc.
Cardiovascular Diseases
France, Netherlands, Germany, Latvia, Sweden, Portugal, Belgium, Lithuania, Czechia, Greece
16/11/2026
Phase II
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
France, Netherlands, Belgium, Spain, Germany, Italy, Slovakia, Sweden, Czechia, Lithuania, Greece, Portugal
16/11/2026
Phase III
Calcilytix Therapeutics Inc.
Hormonal diseases
France, Italy, Spain, Czechia, Netherlands, Denmark, Germany, Hungary
16/11/2026
Phase II
Faron Pharmaceuticals Oy
Hemic and Lymphatic Diseases
Finland, France, Czechia, Poland
13/11/2026
Phase III
Rapport Therapeutics Inc.
Nervous System Diseases
Netherlands, Austria, Czechia, Belgium, Slovakia, Finland, Poland, Spain, Ireland, Sweden, Germany, Hungary, Denmark, Italy, Portugal
11/11/2026
Phase III
Merck Sharp & Dohme LLC
Eye Diseases
Portugal, Austria, Spain, Czechia, Hungary, France, Poland
11/11/2026
Phase III
Seismic Pharmaceuticals Operations LLC
Cardiovascular Diseases
Spain, Portugal, Bulgaria, Italy, Poland, Romania, Czechia, Greece
10/11/2026
Phase III
Vanda Pharmaceuticals Inc.
Digestive System Diseases
Czechia, Estonia, Bulgaria, Romania, Latvia, Poland
10/11/2026
Phase III
Novartis Pharma AG
Neoplasms
Czechia, Portugal, Germany, Austria, Poland, Belgium, Spain, Netherlands, Italy, France, Slovakia
10/11/2026
Phase II
UCB Biopharma
Respiratory Tract Diseases
Italy, Netherlands, Poland, Belgium, Spain, France, Czechia, Bulgaria, Germany, Slovakia
09/11/2026
Phase III
Priovant Therapeutics Inc.
Skin and Connective Tissue Diseases
Belgium, Czechia, Poland, Netherlands, France, Italy, Spain, Hungary, Germany
06/11/2026
Phase III
Hunan Mabgeek Biotech Co. Ltd.
Skin and Connective Tissue Diseases
Czechia, Spain, Poland
04/11/2026
Phase III
Nektar Therapeutics
Skin and Connective Tissue Diseases
Lithuania, Slovakia, Bulgaria, Greece, Czechia, Poland, Spain, Belgium, Germany
03/11/2026
Phase III
Nektar Therapeutics
Immune System Diseases
Portugal, Austria, Poland, Latvia, Italy, Czechia, Germany, Hungary, Croatia
03/11/2026
Phase I
Polpharma Biologics International AG
Nervous System Diseases
Poland, Croatia, Czechia, Bulgaria
02/11/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Hungary, Belgium, Lithuania, Spain, France, Germany, Netherlands, Poland, Denmark, Slovakia, Italy, Austria, Bulgaria, Portugal, Greece, Czechia, Sweden
30/10/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Czechia, Poland, Austria, Italy, Spain, Sweden, Germany, France, Netherlands, Portugal, Finland, Greece
27/10/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Czechia, Germany, Poland
27/10/2026
Phase III
Celcuity Inc.
Neoplasms
Finland, Bulgaria, Portugal, Germany, Greece, Romania, Poland, Hungary, Czechia, Italy, Denmark, Belgium, France, Spain
27/10/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Portugal, Bulgaria, Germany, Croatia, Hungary, Czechia, Romania, Spain, Italy, Denmark, Slovakia, Greece, Poland
23/10/2026
Phase I
Bioequivalence Study of Empagliflozin
2026-526377-41-00Not applicable (submitted trial is a BE study in healthy pa…
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Nutritional and Metabolic Diseases
Czechia
21/10/2026
Phase I/II
SOTIO Biotech a.s.
Neoplasms
Czechia, Spain, France, Belgium
20/10/2026
Phase III
AstraZeneca AB
Musculoskeletal Diseases
Netherlands, Belgium, Bulgaria, Romania, Italy, Germany, Austria, Spain, Portugal, Greece, Czechia, Poland, France
20/10/2026
Phase III
Newave Pharmaceutical Inc.
Hemic and Lymphatic Diseases
Poland, Germany, Spain, Czechia, Italy, France
20/10/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Spain, Poland, France, Italy, Germany, Czechia, Romania, Hungary
15/10/2026
Phase III
Ferrer Internacional S.A., Prilenia Therapeutics B.V.
Nervous System Diseases
Spain, Italy, Portugal, Poland, France, Netherlands, Germany, Belgium, Czechia
12/10/2026
Phase III
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Italy, Austria, Greece, Ireland, Bulgaria, Poland, Sweden, Belgium, Germany, Spain, Czechia, France, Romania, Hungary
08/10/2026
Phase III
AstraZeneca AB
Nutritional and Metabolic Diseases
Italy, Czechia, Germany, Bulgaria, France, Poland
08/10/2026
Phase III
Vivus B.V., Vivus LLC
Respiratory Tract Diseases
Italy, France, Czechia, Poland, Latvia, Germany, Spain
05/10/2026
Phase II
Argenx
Not possible to specify
Spain, Poland, Czechia, Belgium, Italy
05/10/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Austria, Portugal, Slovakia, Italy, Poland, Hungary, Spain, Czechia, France, Netherlands, Germany
05/10/2026
Phase III
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Portugal, Germany, Italy, Czechia, Austria, Spain, Belgium, Netherlands, Poland, Sweden, Greece, Latvia, Hungary, Bulgaria, Romania
29/09/2026
Phase II
Expedition Therapeutics Inc.
Respiratory Tract Diseases
Italy, Germany, Spain, Poland, Czechia, Romania, Hungary, Denmark, Bulgaria
29/09/2026
Phase III
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands
29/09/2026
Phase III
Dianthus Therapeutics Inc.
Immune System Diseases
Czechia, Portugal, Austria, Bulgaria, Germany, France, Latvia, Poland, Italy, Spain, Denmark
28/09/2026
Phase II
Agomab Spain S.L.U.
Digestive System Diseases
France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands
21/09/2026
Phase III
Amgen Inc.
Nutritional and Metabolic Diseases
Czechia, Spain, Poland, Denmark, Germany, Italy, Belgium, Finland
21/09/2026
Phase III
Amgen Inc.
Nutritional and Metabolic Diseases
Germany, Hungary, Czechia, Italy, Poland, Bulgaria
21/09/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia
21/09/2026
Phase II
AnaCardio AB
Cardiovascular Diseases
Czechia, Slovakia, Spain, Bulgaria, Netherlands, Italy, Poland, Germany, Sweden, Hungary
21/09/2026
Phase III
Celea Therapeutics Inc.
Respiratory Tract Diseases
Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands
18/09/2026
Phase II
Corvus Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Italy, Czechia, Germany, Poland, Spain, Bulgaria
18/09/2026
Phase III
Genmab A/S
Neoplasms
Czechia, Netherlands, Lithuania, Ireland, Finland, Hungary, Spain, Greece, Italy, France, Germany, Poland
18/09/2026
Phase III
Ascletis Pharma (China) Co. Ltd.
Nutritional and Metabolic Diseases
Germany, Greece, Czechia, Poland
18/09/2026
Phase III
Aura Biosciences Inc.
Neoplasms
Austria, Netherlands, Belgium, Czechia, Spain, France, Germany, Italy
17/09/2026
Phase III
Pharmacosmos A/S
Neoplasms
Czechia, Greece, France, Belgium, Italy, Spain, Germany
17/09/2026
Phase III
Ascletis Pharma (China) Co. Ltd.
Nutritional and Metabolic Diseases
Germany, Czechia, Greece, Poland
17/09/2026
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Czechia, Greece, France, Italy, Germany, Spain, Poland, Netherlands, Bulgaria
16/09/2026
Phase III
Amgen Inc.
Digestive System Diseases
Belgium, Germany, Hungary, Czechia, Bulgaria, France, Netherlands, Italy, Poland, Greece, Portugal, Spain
16/09/2026
Phase II
Eli Lilly & Co.
Respiratory Tract Diseases
Denmark, France, Romania, Czechia, Poland, Hungary, Germany, Austria
15/09/2026
Phase II
H. Lundbeck A/S
Nervous System Diseases
Czechia, France, Spain, Poland, Italy, Germany, Sweden
15/09/2026
Phase II
Enveda Therapeutics Inc.
Skin and Connective Tissue Diseases
Germany, Czechia, Bulgaria, Poland, Spain
10/09/2026
Phase II
Neurocrine Biosciences Inc.
Nervous System Diseases
Bulgaria, Croatia, Romania, Slovakia, Czechia
07/09/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark
02/09/2026
Phase II
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Hemic and Lymphatic Diseases
Czechia, Denmark, Croatia, Spain, Sweden, Finland, Portugal, Ireland, Netherlands, Belgium, Norway
31/08/2026
Phase II
Idorsia Pharmaceuticals Ltd.
Skin and Connective Tissue Diseases
Czechia, Poland
26/08/2026
Phase II
Apollo Therapeutics Limited
Skin and Connective Tissue Diseases
Hungary, Czechia, Germany, Bulgaria, Poland, Spain
25/08/2026
Phase I
Bioavailability Comparison of Valsartan 320 mg Tablets (Test vs. Reference Product)
2026-527569-31-00Not applicable (submitted trial is a BE study in healthy pa…
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Cardiovascular Diseases
Czechia
25/08/2026
Phase III
Biocodex
Nervous System Diseases
Bulgaria, France, Romania, Czechia
24/08/2026
Phase III
Laboratorios Farmaceuticos Rovi S.A.
Neoplasms
Romania, Spain, Bulgaria, Czechia, Latvia, Poland, Croatia, Slovakia
21/08/2026
Phase III
Deciphera Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Austria, Czechia, Italy, Portugal, Germany, France, Hungary, Spain, Poland
21/08/2026
Phase III
Amgen Inc.
Eye Diseases
Slovakia, Latvia, Czechia, Poland, Spain, Hungary, Lithuania
17/08/2026
Phase II
Cardurion Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Slovakia, Lithuania, Hungary, Italy, Netherlands, Spain, Poland, Bulgaria, Czechia
14/08/2026
Phase I
Bioequivalence of Estradiol 10 mcg Vaginal Tablets in Healthy Women Participants.
2026-526477-42-00Not applicable (submitted trial is a bioavailability trial …
Laboratorios Leon Farma S.A.
Female Urogenital Diseases and Pregnancy Complications
Czechia
14/08/2026
Phase I
Bioavailability Comparison of Finerenone 20 mg Tablets (Test vs. Comparator Product).
2026-527382-30-00Comparative bioavailability study under fasting conditions.
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Cardiovascular Diseases
Czechia
12/08/2026
Phase I
Orion Corporation
Nervous System Diseases
Czechia
10/08/2026
Phase III
Argenx
Hormonal diseases
Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria
07/08/2026
Phase III
AstraZeneca AB
Nutritional and Metabolic Diseases
Poland, Germany, Bulgaria, Czechia
04/08/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Skin and Connective Tissue Diseases
Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania
03/08/2026
Phase III
Janssen Cilag International
Immune System Diseases
Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece
03/08/2026
Phase III
Janssen Cilag International
Immune System Diseases
France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal
03/08/2026
Phase I
Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions
2026-525836-41-00Not applicable (submitted trial is a bioavailability trial …
Laboratorios Cinfa S.A.
Nervous System Diseases
Czechia
30/07/2026
Phase III
AstraZeneca AB
Cardiovascular Diseases
Spain, Hungary, Germany, Poland, Italy, Bulgaria, Netherlands, Austria, Romania, Sweden, France, Greece, Slovakia, Czechia
29/07/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium
27/07/2026
Phase III
AstraZeneca AB
Cardiovascular Diseases
Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany
24/07/2026
Phase III
Neurocrine Biosciences Inc.
Hormonal diseases
Czechia, Germany, Sweden, Portugal, Romania, Bulgaria, Italy, Austria, Spain, Belgium
23/07/2026
Phase III
Chemo Research S.L.
Not possible to specify
Sweden, Czechia, Spain, Hungary, Poland, Finland, Romania
23/07/2026
Phase III
Ipsen Bioscience Inc.
Digestive System Diseases
Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway
21/07/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary
20/07/2026
Phase I/II
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Germany, Poland, Czechia, Belgium, France, Greece, Sweden, Portugal, Italy
13/07/2026
Phase III
Grifols Therapeutics LLC
Nervous System Diseases
Romania, Czechia, Poland
07/07/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Romania, Greece, Norway, Netherlands, Poland, Lithuania, Czechia, Slovakia, Spain
06/07/2026
Phase I
Bioequivalence Study of Dapagliflozin 10 mg
2026-526840-10-00Not applicable (submitted trial is a BE study in healthy pa…
Vipharm S.A.
Cardiovascular Diseases
Czechia
02/07/2026
Phase III
Janssen Cilag International
Neoplasms
Poland, Spain, Czechia, France, Italy, Germany, Greece
01/07/2026
Phase III
Genmab A/S
Neoplasms
Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland
01/07/2026
Phase III
Insmed Inc.
Respiratory Tract Diseases
Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania
30/06/2026
Phase III
Merck Healthcare KGaA
Skin and Connective Tissue Diseases
Germany, Romania, France, Bulgaria, Belgium, Spain, Poland, Greece, Italy, Czechia
29/06/2026
Phase III
Hamlet BioPharma AB
Male Urogenital Diseases
Czechia
29/06/2026
Phase III
Schneider Children's Medical Center Of Israel
Musculoskeletal Diseases
Greece, Poland, France, Czechia
23/06/2026
Phase III
Adarx Pharmaceuticals Inc.
Immune System Diseases
Poland, Italy, Hungary, France, Austria, Czechia, Belgium, Spain, Bulgaria, Germany, Croatia
22/06/2026
Phase III
Zenas Biopharma (USA) LLC
Nervous System Diseases
Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia
22/06/2026
Phase I
A Phase 1 first-in-human study to evaluate SAR448272 in adult participants
2026-526014-87-00immunological diseases, healthy volunteers
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Czechia, France, Spain, Italy
19/06/2026
Phase II
Spyre Therapeutics Inc.
Digestive System Diseases
Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania
16/06/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Musculoskeletal Diseases
France, Netherlands, Germany, Czechia, Belgium, Austria, Hungary, Greece, Spain
15/06/2026
Phase IV
Swedish Orphan Biovitrum AB (publ)
Immune System Diseases
France, Italy, Spain, Germany, Austria, Belgium, Czechia
15/06/2026
Phase I
Pevisal Group Farmaceutici S.r.l.
Reproductive and Urinary Physiological Phenomena
Czechia
12/06/2026
Phase II
Eli Lilly & Co.
Digestive System Diseases
Latvia, Portugal, Greece, France, Czechia, Italy, Poland, Slovakia, Hungary, Croatia, Lithuania
10/06/2026
Phase III
Kardigan Inc.
Cardiovascular Diseases
Norway, Czechia, Portugal, Austria, Poland, France, Spain
08/06/2026
Phase III
Zai Lab (US) LLC
Neoplasms
Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France, Croatia, Romania, Norway
08/06/2026
Phase II
Pfizer Inc.
Respiratory Tract Diseases
Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary
08/06/2026
Phase III
Eyebiotech Limited
Eye Diseases
Austria, Slovakia, Portugal, Czechia, Hungary, Spain, France, Denmark, Italy, Croatia
05/06/2026
Phase III
Alkermes Inc.
Nervous System Diseases
Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland
04/06/2026
Phase I
Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Subjects Under Fed Conditions
2026-525780-41-00Not applicable (submitted trial is a bioavailability trial …
Laboratorios Cinfa S.A.
Nervous System Diseases
Czechia
04/06/2026
Phase II
Fakultni Nemocnice Kralovske Vinohrady
Otorhinolaryngologic Diseases
Czechia
02/06/2026
Phase I
Adamed Pharma S.A.
Cardiovascular Diseases
Czechia
02/06/2026
Phase III
Alkermes Inc.
Nervous System Diseases
Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland
02/06/2026
Phase III
Innocare Pharma Inc.
Neoplasms
Poland, France, Czechia, Spain, Romania
01/06/2026
Phase II
Centre Hospitalier De Versailles
Hemic and Lymphatic Diseases
Germany, France, Czechia, Netherlands, Spain
29/05/2026
Phase III
Novartis Pharma AG
Neoplasms
Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France
29/05/2026
Phase II
Vertex Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark
29/05/2026
Phase IV
Fakultni Nemocnice Brno
Female Urogenital Diseases and Pregnancy Complications
Czechia
28/05/2026
Phase III
Janssen Cilag International
Immune System Diseases
Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary
27/05/2026
Phase II
Maplight Therapeutics Inc.
Mental Disorders
Italy, Poland, Czechia, Portugal, Bulgaria, France, Slovakia, Romania, Hungary
27/05/2026
Phase I/II
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia
26/05/2026
Phase I
A study comparing different dosage forms of midazolam and how they are taken up in the body.
2025-524999-37-00Bioavailability Study under Fasting Conditions
MIDAS Pharma GmbH
Anesthesia and Analgesia
Czechia
26/05/2026
Phase I
Orion Corporation
Nervous System Diseases
Czechia
22/05/2026
Phase II
Pharming Technologies B.V.
Metabolism
Belgium, Germany, Czechia, Spain, Denmark, Italy, France, Netherlands
21/05/2026
Phase III
Novartis Pharma AG
Skin and Connective Tissue Diseases
Germany, Spain, France, Poland, Bulgaria, Czechia
20/05/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy, Romania, Denmark
20/05/2026
Phase III
VarmX B.V.
Hemic and Lymphatic Diseases
Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania
19/05/2026
Phase III
Zenas Biopharma (USA) LLC
Nervous System Diseases
Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary
18/05/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Portugal, Norway, Sweden, Bulgaria, France, Belgium, Austria, Germany, Finland, Poland, Romania, Netherlands, Spain, Italy, Hungary, Czechia
15/05/2026
Phase III
Deciphera Pharmaceuticals Inc.
Nervous System Diseases
Czechia, Germany, Italy, Belgium, Spain, Poland, Austria, France, Hungary
14/05/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway
13/05/2026
Phase III
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Germany, Romania, Czechia, Poland, Hungary, France, Spain, Italy
13/05/2026
Phase II
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Germany, France, Norway
12/05/2026
Phase III
Generate Biomedicines Inc.
Respiratory Tract Diseases
Latvia, Hungary, Bulgaria, Romania, Portugal, Netherlands, Croatia, Germany, Greece, Czechia
12/05/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Czechia, Sweden, Poland, Netherlands, Greece, Latvia, Finland, Norway, Belgium, Austria, Portugal, Romania, Italy, Estonia, France, Ireland, Germany, Spain, Bulgaria, Hungary
12/05/2026
Phase III
Takeda Development Center Americas Inc.
Musculoskeletal Diseases
Germany, Belgium, Spain, Czechia, Croatia, Portugal, Poland, Latvia, Bulgaria, France, Estonia, Hungary, Italy
12/05/2026
Phase III
A. Menarini International Licensing S.A.
Hemic and Lymphatic Diseases
Spain, Poland, Netherlands, Italy, Slovakia, Czechia, Germany
11/05/2026
Phase III
Octapharma Pharmazeutika Produktionsgesellschaft mbH
Immune System Diseases
Czechia, Lithuania, Greece, Poland, Germany, Latvia, Bulgaria, Italy
11/05/2026
Phase III
Eli Lilly & Co.
Neoplasms
Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany
11/05/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland
11/05/2026
Phase III
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Poland, Hungary, France, Belgium, Italy, Netherlands, Czechia, Germany, Spain
07/05/2026
Phase III
Dompe' Farmaceutici S.p.A.
Eye Diseases
Czechia, Italy, Netherlands, Poland, Germany, Spain, Hungary, France
05/05/2026
Phase II
Immunovant Sciences GmbH
Immune System Diseases
Italy, Greece, Germany, Hungary, Poland, Czechia, Netherlands, Spain, Belgium, Bulgaria, Latvia
05/05/2026
Phase III
Janssen Cilag International
Immune System Diseases
Denmark, Hungary, Portugal, Italy, Norway, Greece, Slovakia, Czechia, France, Poland, Bulgaria, Germany, Spain, Romania, Finland
05/05/2026
Phase II
Novartis Pharma AG
Eye Diseases
Bulgaria, Romania, Germany, Czechia, Spain, Poland, Italy, Hungary, France
04/05/2026
Phase III
Kailera Therapeutics Inc.
Nutritional and Metabolic Diseases
Hungary, Poland, Bulgaria, Germany, Czechia, Spain
04/05/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Belgium, France, Czechia, Croatia, Greece, Germany, Italy, Spain
04/05/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece
04/05/2026
Phase I
Regeneron Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Belgium, Czechia, Germany, Poland
30/04/2026
Phase III
Inhibikase Therapeutics Inc.
Cardiovascular Diseases
Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania
28/04/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark
28/04/2026
Phase I
Safety of stem cells in treatmemt of retinal diseases.
2023-503573-38-00Retinal degenerative diseases
Bioinova a.s.
Eye Diseases
Czechia
28/04/2026
Phase III
Epygenix Therapeutics Inc.
Nervous System Diseases
Italy, Spain, Hungary, Romania, Czechia, Poland
28/04/2026
Phase III
Exciva GmbH
Nervous System Diseases
Italy, Slovakia, Spain, Poland, Czechia, Germany
28/04/2026
Phase II
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania
27/04/2026
Phase III
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Czechia, France, Romania, Germany, Poland, Bulgaria, Spain
27/04/2026
Phase II
AstraZeneca AB
Neoplasms
Italy, Austria, Spain, Ireland, Czechia, Poland
27/04/2026
Phase I
Lakefront Biotherapeutics West LLC
Immune System Diseases
Czechia
21/04/2026
Phase III
BeOne Medicines I GmbH
Neoplasms
Netherlands, Poland, Italy, Germany, Spain, Romania, Czechia, France, Sweden
20/04/2026
Phase II
CSL Behring LLC
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands
20/04/2026
Phase I
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Hungary, Czechia, France, Italy, Belgium
20/04/2026
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France
17/04/2026
Phase III
Metsera Inc.
Nutritional and Metabolic Diseases
Czechia, Bulgaria, Slovakia, Spain, Hungary, Germany, Romania, Poland
16/04/2026
Phase III
Guerbet, Bracco Imaging S.p.A.
Cardiovascular Diseases
Italy, France, Czechia, Hungary, Spain, Germany, Poland
15/04/2026
Phase II
Pfizer Inc.
Skin and Connective Tissue Diseases
Poland, Czechia, Germany, Bulgaria, France
14/04/2026
Phase III
Praxis Precision Medicines Inc.
Nervous System Diseases
Poland, Germany, Czechia, Italy, Spain
10/04/2026
Phase III
Alfasigma S.p.A.
Musculoskeletal Diseases
Spain, Bulgaria, France, Belgium, Germany, Greece, Italy, Poland, Hungary, Czechia
07/04/2026
Phase III
Metsera Inc.
Nutritional and Metabolic Diseases
Germany, Hungary, Slovakia, Poland, Spain, Czechia, Romania, Bulgaria
02/04/2026
Phase III
Alfasigma S.p.A.
Immune System Diseases
France, Germany, Poland, Belgium, Hungary, Spain, Czechia, Greece, Italy
01/04/2026
Phase II
Bluefin Biomedicine Inc.
Immune System Diseases
Spain, Germany, Czechia, Poland, Bulgaria
31/03/2026
Phase IV
Fakultni Nemocnice V Motole
Nervous System Diseases
Czechia, Poland
30/03/2026
Phase I
Orion Corporation
Nervous System Diseases
Czechia
27/03/2026
Phase III
AstraZeneca AB
Pathological Conditions, Signs and Symptoms
Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany
27/03/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Germany, Spain, Poland, Czechia, Slovakia
24/03/2026
Phase III
Tenax Therapeutics Inc.
Cardiovascular Diseases
France, Italy, Germany, Czechia, Austria, Poland, Hungary, Bulgaria, Spain
24/03/2026
Phase III
Pfizer Inc.
Neoplasms
France, Italy, Hungary, Greece, Czechia, Spain, Poland, Germany
24/03/2026
Phase II
Janssen Cilag International
Immune System Diseases
Spain, Poland, Czechia, Germany, Hungary
20/03/2026
Phase II
Fakultni Nemocnice Ostrava
Cardiovascular Diseases
Czechia
19/03/2026
Phase IV
Institute For Clinical And Experimental Medicine
Digestive System Diseases
Czechia
18/03/2026
Phase II
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Belgium, France, Poland, Germany, Spain, Czechia
18/03/2026
Phase I/II
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
2024-516896-34-00progressive/relapsed/refractory pediatric low-grade glioma …
Universitaetsklinikum Heidelberg AöR
Nervous System Diseases
Denmark, Czechia, Austria, Sweden, Germany
17/03/2026
Phase III
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland
16/03/2026
Phase I
UCB Biopharma
Immune System Diseases
Croatia, Poland, Germany, Czechia, Slovakia, Bulgaria
16/03/2026
Phase III
Liquidia Technologies Inc.
Respiratory Tract Diseases
Latvia, Germany, Italy, Czechia, France, Belgium, Portugal, Poland, Austria, Spain
11/03/2026
Phase I
Bioequivalence Study of Empagliflozin
2026-525434-33-00Not applicable (submitted trial is a BE study in healthy pa…
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Nutritional and Metabolic Diseases
Czechia
11/03/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Sweden, Czechia, Belgium, Romania, Netherlands, Italy, France, Spain, Germany, Poland, Austria
10/03/2026
Phase II
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary
06/03/2026
Phase III
Alvotech Swiss AG
Eye Diseases
Latvia, Slovakia, Czechia, Hungary, Poland, Bulgaria
06/03/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase III
MoonLake Immunotherapeutics AG
Musculoskeletal Diseases
Estonia, Croatia, Slovakia, Lithuania, Romania, Hungary, Germany, France, Latvia, Poland, Portugal, Greece, Czechia, Bulgaria, Finland, Spain
25/02/2026
Phase II
Draig Therapeutics Limited
Mental Disorders
Czechia, Bulgaria, Poland
24/02/2026
Phase III
Eli Lilly & Co.
Cardiovascular Diseases
Germany, Czechia, Lithuania, Spain, Austria, France, Hungary, Greece, Estonia, Netherlands, Slovakia, Poland, Romania, Bulgaria, Italy, Belgium
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Spain, Czechia, Lithuania, Hungary, Greece, Bulgaria, Poland, Belgium, France, Germany, Norway, Austria, Netherlands, Italy, Slovakia
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Netherlands, Poland, Greece, Czechia, Italy, Bulgaria, Belgium, Germany, Lithuania, Austria, Spain, Hungary, Norway, France
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase III
Kura Oncology Inc.
Neoplasms
Belgium, Spain, Italy, Czechia, Hungary, Poland, France, Portugal, Germany, Greece
20/02/2026
Phase III
Olema Pharmaceuticals Inc.
Neoplasms
Hungary, Portugal, Italy, France, Poland, Czechia, Germany, Spain, Belgium, Austria, Romania, Greece, Netherlands
17/02/2026
Phase II
Pediatric Research International GmbH
Neoplasms
Denmark, Italy, Czechia, Sweden, Poland, Netherlands, Germany, Austria
16/02/2026
Phase I
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, France, Hungary, Poland, Spain, Bulgaria
16/02/2026
Phase III
CatalYm GmbH
Nutritional and Metabolic Diseases
France, Czechia, Romania, Italy, Germany, Poland, Spain, Bulgaria, Norway, Ireland, Netherlands
13/02/2026
Phase III
Syndax Pharmaceuticals Inc.
Neoplasms
Greece, Poland, Spain, Austria, Italy, Romania, Belgium, France, Lithuania, Germany, Hungary, Czechia, Portugal
13/02/2026
Phase III
Regeneron Pharmaceuticals Inc.
Neoplasms
Greece, Spain, Poland, Italy, Austria, Czechia, Belgium, Germany, Netherlands, France
10/02/2026
Phase III
Amgen Inc.
Respiratory Tract Diseases
Poland, Germany, Czechia, Hungary, Spain, France
10/02/2026
Phase III
Argenx
Nervous System Diseases
Czechia, Denmark, Poland, Slovenia, Netherlands, Austria, Estonia, Slovakia, Hungary, Finland, Bulgaria, France, Italy, Greece, Romania
10/02/2026
Phase III
Astria Therapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Netherlands, Spain, Poland, Germany, Czechia, Austria, Portugal, Hungary, France, Italy, Bulgaria
09/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Germany, Austria, Italy, Czechia, Netherlands, Poland, Belgium, Hungary, Lithuania, Greece, France, Bulgaria, Spain, Norway
09/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Austria, France, Norway, Hungary, Bulgaria, Netherlands, Czechia, Slovakia, Germany, Lithuania, Greece, Belgium, Italy, Spain, Poland
09/02/2026
Phase II
Biogen Idec Research Limited
Immune System Diseases
Germany, Austria, Spain, Czechia, France
09/02/2026
Phase IV
Masarykova Univerzita
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Czechia
09/02/2026
Phase III
Mb Pharma Group s.r.o.
Skin and Connective Tissue Diseases
Czechia
09/02/2026
Phase I
Oxytone Bioscience B.V.
Female Urogenital Diseases and Pregnancy Complications
Czechia
09/02/2026
Phase I
Faes Farma S.A.
Not possible to specify
Czechia
06/02/2026
Phase III
Mirum Pharmaceuticals Inc.
Virus Diseases
Czechia, Austria, Spain, Romania, Germany, Italy, France
03/02/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Finland, Germany, Italy, France, Sweden, Poland, Spain, Belgium, Czechia, Netherlands, Portugal, Norway
03/02/2026
Phase III
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria
03/02/2026
Phase III
Ideaya Biosciences Inc.
Eye Diseases
France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany, Slovenia
29/01/2026
Phase III
Amgen Inc.
Respiratory Tract Diseases
Poland, Czechia, Germany, Hungary, France, Spain
27/01/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Czechia, France, Netherlands, Bulgaria, Norway, Austria, Poland, Spain, Italy, Hungary, Germany, Romania, Sweden, Portugal, Belgium
27/01/2026
Phase III
Insmed Inc.
Respiratory Tract Diseases
Portugal, Italy, Czechia, Poland, Denmark, Greece, Germany, Romania, Spain, France, Belgium, Austria
26/01/2026
Phase III
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Germany, Spain, Belgium, Czechia, Norway, France, Poland, Netherlands, Italy, Finland
26/01/2026
Phase III
Xenon Pharmaceuticals Inc.
Mental Disorders
Spain, Czechia, Slovakia, Romania, Poland, Finland, Germany
26/01/2026
Phase III
Arrowhead Pharmaceuticals Inc.
Cardiovascular Diseases
Greece, France, Belgium, Germany, Netherlands, Austria, Sweden, Spain, Czechia, Italy
23/01/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Romania, Bulgaria, Germany, Spain, Czechia, France, Hungary, Italy, Sweden, Poland, Denmark, Belgium
19/01/2026
Phase III
Janssen Cilag International
Neoplasms
Italy, Portugal, Spain, Romania, Hungary, France, Czechia, Germany, Netherlands, Austria, Poland, Belgium
14/01/2026
Phase II
Novartis Pharma AG
Skin and Connective Tissue Diseases
France, Germany, Poland, Czechia, Bulgaria
14/01/2026
Phase II
AstraZeneca AB
Not possible to specify
Germany, France, Spain, Italy, Belgium, Czechia, Greece, Denmark, Hungary
14/01/2026
Phase I
To evaluate the pharmacokinetics and safety of nolasiban
2025-523706-32-00not applicable (submitted trial is a pharmacokinetic study …
ReproNovo ApS
Female Urogenital Diseases and Pregnancy Complications
Czechia
09/01/2026
Phase I/II
35Pharma Inc.
Cardiovascular Diseases
Hungary, Spain, Poland, Germany, Czechia
23/12/2025
Phase II
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Poland, Hungary, Netherlands, Germany, Czechia, Spain, France, Italy, Greece
22/12/2025
Phase III
Pfizer Inc.
Not possible to specify
Belgium, Finland, France, Germany, Netherlands, Bulgaria, Spain, Slovakia, Italy, Czechia, Poland, Greece
22/12/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Male Urogenital Diseases
Ireland, Belgium, Germany, Italy, Norway, Spain, Austria, Sweden, France, Romania, Czechia
19/12/2025
Phase III
Biohaven Therapeutics Ltd.
Nervous System Diseases
Germany, France, Italy, Belgium, Czechia, Poland, Austria, Netherlands, Spain, Portugal
15/12/2025
Phase III
Vertex Pharmaceuticals Inc.
Immune System Diseases
Hungary, Ireland, Czechia, Italy, Spain, Germany, Netherlands
12/12/2025
Phase III
Universita Degli Studi Di Milano Bicocca
Neoplasms
France, Lithuania, Norway, Finland, Spain, Italy, Czechia, Germany, Hungary, Slovakia, Denmark, Austria, Netherlands
09/12/2025
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Germany, France, Belgium, Italy, Denmark, Netherlands, Spain, Czechia, Sweden
09/12/2025
Phase III
Charite Universitaetsmedizin Berlin KöR
Hemic and Lymphatic Diseases
Netherlands, Czechia, Italy, Spain, Denmark, Austria, Norway, Sweden, Germany, France, Finland, Belgium, Slovenia
09/12/2025
Phase II
Novartis Pharma AG
Hemic and Lymphatic Diseases
Germany, Czechia, Belgium, Spain, Italy, Bulgaria, Romania, France, Hungary
08/12/2025
Phase II
Bayer AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Italy, Poland, Czechia, Germany, Portugal, France
05/12/2025
Phase III
Bayer AG
Cardiovascular Diseases
Czechia, Germany, Greece, Italy, Finland, Bulgaria, Belgium, Poland, Austria, Portugal, Spain, Hungary, Sweden
05/12/2025
Phase III
Bayer AG
Cardiovascular Diseases
Czechia, Poland, Portugal, Austria, Finland, Greece, Bulgaria, Sweden, Spain, Italy, Belgium, Hungary, Germany
05/12/2025
Phase III
Zealand Pharma A/S
Digestive System Diseases
Finland, France, Belgium, Germany, Hungary, Spain, Austria, Netherlands, Italy, Denmark, Czechia, Norway, Poland, Sweden, Estonia
04/12/2025
Phase III
AbbVie Deutschland GmbH & Co. KG
Eye Diseases
Czechia, Portugal, Hungary, Spain, Belgium, Italy, Austria, France, Slovakia, Croatia, Germany, Bulgaria, Greece
02/12/2025
Phase II
Pfizer Inc.
Cardiovascular Diseases
Italy, Czechia, Germany, Greece, Spain, Belgium, France
02/12/2025
Phase III
UCB Biopharma
Immune System Diseases
Czechia, Denmark, Spain, Poland, Germany, Hungary, Italy, France
02/12/2025
Phase III
Janssen Cilag International
Immune System Diseases
Netherlands, Italy, Portugal, Spain, Czechia, Romania, France, Sweden, Hungary, Belgium, Germany, Greece, Poland
01/12/2025
Phase III
Adamed Pharma S.A.
Bacterial Infections and Mycoses
Italy, Czechia, Poland, Slovakia
01/12/2025
Phase III
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Czechia, Germany, Sweden, Greece, Croatia, Belgium, Poland, Spain, Portugal, Italy, Denmark, France, Netherlands
01/12/2025
Phase III
Argenx
Nervous System Diseases
Czechia, Bulgaria, Netherlands, Hungary, Sweden, Slovakia, Slovenia, Greece, Norway, Poland, Italy, Spain, Estonia, Denmark, France, Romania, Portugal, Austria, Germany
01/12/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Czechia, Austria, Belgium, Ireland, Spain, Germany, Romania, Netherlands, Slovakia, Greece, Poland, Italy, Denmark, France, Sweden
28/11/2025
Phase II
Spyre Therapeutics Inc.
Immune System Diseases
Czechia, Poland, Spain, Bulgaria
25/11/2025
Phase III
Arcus Biosciences Inc.
Neoplasms
Italy, Spain, Romania, Germany, Netherlands, Poland, France, Czechia, Hungary
24/11/2025
Phase III
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Czechia, Greece, Latvia, Austria, Germany, Bulgaria, Romania, Italy
24/11/2025
Phase I
A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment
2024-517923-38-00Newly diagnosed and/or previously treated IDH1-mutated mali…
Institut De Recherches Internationales Servier IRIS
Neoplasms
Czechia, Spain
24/11/2025
Phase II
Gesynta Pharma AB
Female Urogenital Diseases and Pregnancy Complications
Italy, Hungary, Poland, Czechia, Bulgaria, Romania
21/11/2025
Phase III
Pfizer Inc.
Neoplasms
Greece, Italy, Belgium, Slovakia, Czechia, Germany, France, Poland, Denmark, Spain, Netherlands, Sweden, Finland, Bulgaria
17/11/2025
Phase III
AstraZeneca AB
Neoplasms
Italy, Netherlands, Lithuania, Finland, Greece, Austria, Belgium, Hungary, Spain, Poland, Czechia, Germany, France, Denmark, Slovenia
17/11/2025
Phase III
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.
2025-522052-13-00Framework for Optimizing, Refining, and Unifying Management…
Ospedale Pediatrico Bambino Gesu
Hemic and Lymphatic Diseases
Germany, Denmark, Finland, Norway, Austria, Italy, Poland, France, Czechia, Belgium, Croatia, Hungary, Lithuania, Sweden, Netherlands, Slovakia, Spain
17/11/2025
Phase III
Relay Therapeutics Inc.
Neoplasms
Hungary, Spain, Italy, Belgium, Netherlands, Austria, Germany, Greece, Czechia, Denmark, Poland, Bulgaria, Portugal, France, Ireland, Romania
11/11/2025
Phase II
Spyre Therapeutics Inc.
Digestive System Diseases
Belgium, Hungary, Lithuania, Netherlands, Croatia, Czechia, Bulgaria, Romania, Spain, France, Austria, Italy, Greece, Poland, Germany, Slovakia
10/11/2025
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Greece, Germany, France, Italy, Croatia, Denmark, Czechia, Austria, Belgium, Ireland, Spain, Poland
10/11/2025
Phase II
Seaport Therapeutics Inc.
Mental Disorders
Bulgaria, Czechia, Germany, Poland, Hungary, Slovakia, Romania
06/11/2025
Phase III
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Bulgaria, Spain, Netherlands, Italy, Poland, Greece, Germany, France, Czechia, Croatia, Norway, Sweden
04/11/2025
Phase III
Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
Neoplasms
Germany, France, Italy, Austria, Netherlands, Spain, Czechia, Belgium
04/11/2025
Phase III
Otsuka Pharmaceutical Development & Commercialization Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Czechia, Italy, Spain, Netherlands, Poland, France, Germany
03/11/2025
Phase III
Acadia Pharmaceuticals Inc.
Nervous System Diseases
Czechia, Italy, France, Bulgaria
03/11/2025
Phase I/II
Glaxosmithkline Research & Development Limited
Neoplasms
Estonia, Czechia, Spain, Romania, Italy, Denmark, Belgium, Greece
03/11/2025
Phase II
Bluefin Biomedicine Inc.
Immune System Diseases
Poland, Bulgaria, Germany, Czechia, Spain
31/10/2025
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Czechia, Romania, Croatia, Slovakia, Hungary
29/10/2025
Phase II
Acadia Pharmaceuticals Inc.
Nervous System Diseases
Bulgaria, Czechia, Italy, France
29/10/2025
Phase II
Maplight Therapeutics Inc.
Nervous System Diseases
France, Czechia, Slovakia, Hungary, Portugal, Romania, Bulgaria, Italy, Poland
27/10/2025
Phase III
BioNTech SE
Female Urogenital Diseases and Pregnancy Complications
Denmark, Poland, Italy, Finland, Czechia, Sweden, Greece, Belgium, Norway, Hungary, Germany, Austria, France, Spain, Netherlands
27/10/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Czechia, France, Sweden, Romania, Belgium, Austria, Bulgaria, Italy, Netherlands, Denmark, Germany, Poland, Hungary, Spain, Norway
24/10/2025
Phase III
Adarx Pharmaceuticals Inc.
Immune System Diseases
Belgium, Poland, Italy, Czechia, Hungary, Spain, Germany, Croatia, France, Bulgaria, Austria
22/10/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Poland, Hungary, Italy, France, Czechia
22/10/2025
Phase III
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Poland, Spain, Bulgaria, Italy, Netherlands, Croatia, Germany, Sweden, Greece, Czechia, Norway, France
22/10/2025
Phase II
Ngm Biopharmaceuticals Inc.
Nutritional and Metabolic Diseases
Czechia, Slovakia, Poland, Hungary, Bulgaria
21/10/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Croatia, Romania, France, Spain, Italy, Greece, Czechia, Bulgaria, Poland, Portugal, Hungary
21/10/2025
Rows per page Showing 1–344 of 344
1
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 November 2026. https://priyalifescience.com/clinical-trials-europe/country/czechia

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,893 trial records at the last sync on 20 Nov 2026, 03:17 UTC; this register shows the 2,556 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 344 of those trials with a site in Czechia.

How many recently authorised EU trials have a site in Czechia?

344 of the 2,556 most recently authorised trials in this register list a site in Czechia; 218 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (Czechia), 344 trials
PhaseTrialsShare
Phase III21863.4%
Phase II7421.5%
Phase I3811%
Phase I/II92.6%
Phase IV51.5%

Most active sponsors

Lead sponsors with the most trials (Czechia)
Lead sponsorTrials
Eli Lilly & Co.14
Novartis Pharma AG14
Sanofi-Aventis Recherche & Developpement14
AstraZeneca AB12
Merck Sharp & Dohme LLC11
Janssen Cilag International9
Bristol-Myers Squibb Services Unlimited Company8
Amgen Inc.7
Novo Nordisk A/S7
Regeneron Pharmaceuticals Inc.7
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.